Cbay stock forecast.

Get the latest CymaBay Therapeutics Inc (CBAY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Cbay stock forecast. Things To Know About Cbay stock forecast.

We’ve all flipped between different weather apps, wondering why each is giving a slightly different report. Before we look at AccuWeather, it’s important to understand the basics of weather forecasting. In the past, weather predictions were...CymaBay Therapeutics Inc (CBAY) stock is trading at $11.76 as of 11:26 AM on Monday, Jul 3, a rise of $0.81, or 7.39% from the previous closing price of $10.95. The stock has traded between $10.95 and $11.77 so far today. Volume today is low. So far 1,522,720 shares have traded compared to average volume of 2,310,531 shares.According to the issued ratings of 7 analysts in the last year, the consensus rating for Verastem stock is Buy based on the current 7 buy ratings for VSTM. The average twelve-month price prediction for Verastem is $29.71 with a high price target of $36.00 and a low price target of $21.00. Learn more on VSTM's analyst rating history.CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead ...Dec 1, 2023 · Their VKTX share price targets range from $19.00 to $37.00. On average, they predict the company's stock price to reach $30.25 in the next twelve months. This suggests a possible upside of 132.5% from the stock's current price. View analysts price targets for VKTX or view top-rated stocks among Wall Street analysts.

Stock Price Forecast The 8 analysts offering 12-month price forecasts for Cymabay Therapeutics Inc have a median target of 11.00, with a high estimate of. ... What is The target price for CBAY? The 8 analysts offering 12-month price forecasts for Cymabay Therapeutics Inc have a median target of 11.00, with a high estimate of 14.00 and a low …97.32M. MSFT. 374.51. -1.16%. 29.21M. View today's Cymabay Therapeu stock price and latest CBAY news and analysis. Create real-time notifications to follow any changes in the live stock price.

6 analysts have issued 12 month price objectives for Spruce Biosciences' shares. Their SPRB share price targets range from $4.00 to $10.00. On average, they expect the company's share price to reach $7.67 in the next year. This suggests a possible upside of 463.7% from the stock's current price.You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.

Nov 29, 2023 · Future criteria checks 2/6. CymaBay Therapeutics is forecast to grow earnings and revenue by 47.6% and 61.6% per annum respectively. EPS is expected to grow by 45.7% per annum. Return on equity is forecast to be -57.1% in 3 years. Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...NEWARK, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic ...1 Wall Street research analysts have issued 12 month price objectives for Genus' shares. Their GNS share price targets range from GBX 4,500 to GBX 4,500. On average, they anticipate the company's stock price to reach GBX 4,500 in the next year. This suggests a possible upside of 126.4% from the stock's current price.

Heading out for an outdoor adventure? Whether you’re planning a picnic, a hiking trip, or a beach day, one essential tool you need in your arsenal is a detailed weather 10 day forecast.

The current CymaBay Therapeutics [ CBAY] share price is $17.90. The Score for CBAY is 74, which is 48% above its historic median score of 50, and infers lower risk than normal. CBAY is currently trading in the 70-80% percentile range relative to its historical Stock Score levels.

In a recent transaction on November 17, 2023, Charles Mcwherter, the President of Research and Development at CymaBay Therapeutics Inc (NASDAQ:CBAY), sold 11,342 shares of the company's stock ... (See CBAY stock forecast on TipRanks) AbSci Corporation . For the second penny stock we’ll look at, we’ll stick with the medical tech field – but look at a company with a different take on ...CBAY 8.19%. 70. See CBAY Report. CymaBay Therapeutics Inc ( CBAY) is near the top in its industry group according to InvestorsObserver. CBAY gets an overall rating of 80. That means it scores higher than 80 percent of stocks. CymaBay Therapeutics Inc gets a 91 rank in the Biotechnology industry. Biotechnology is number 13 out of 148 …CymaBay Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. CBAY updated stock price target summary.Cymabay Therapeutics (CBAY) Company Description. CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral ... Nov 30, 2023 · NEWARK, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic disea... 5 weeks ago - GlobeNewsWire What happened. Shares of CymaBay Therapeutics ( CBAY -1.16%) were up more than 37% as of 11:15 a.m. ET on Friday. The clinical-stage biotech saw its shares rise after Ipsen and Genfit announced ...

What are analysts’ forecasts for CBAY stock? Forecst.com predicts future values using technical analysis of a large number of analytical parameters. CBAY stock returns are also predicted based on historical data. According to our research, CBAY stock is a bad long-term investment.Is Cymabay Therapeutics (NASDAQ:CBAY) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, ...In a recent transaction on November 17, 2023, Charles Mcwherter, the President of Research and Development at CymaBay Therapeutics Inc (NASDAQ:CBAY), sold 11,342 shares of the company's stock ... Sep 8, 2023 · CymaBay (CBAY) Stock Up on Positive Results From PBC Study. ... The median home sale price will fall 1.7% next year after eking out an anticipated 0.2% gain in 2023, according to the forecast. há 4 dias ... Cymabay Therapeutics Inc (NASDAQ:CBAY) shares, rose in value on Thursday, November 30, with the stock price up by 3.99% to the previous ...Interactive Chart for CymaBay Therapeutics, Inc. (CBAY), analyze all the data with a huge range of indicators.The average Guardforce Ai Co stock price prediction forecasts a potential upside of 260.82% from the current GFAI share price of $3.88. What is GFAI's forecast return on assets (ROA) for 2023-2026? (NASDAQ: GFAI) forecast ROA is N/A, which is lower than the forecast US Security & Protection Services industry average of N/A.

Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Verastem Inc have a median target of 33.00, with a high estimate of 36.00 and a low estimate of 17.50. The median ...

CBAY Signals & Forecast. Mostly positive signals in the chart today. The Cymabay Therapeutics Inc stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.Dec 1, 2023 · The consensus price target of analysts on Wall Street is $24.42, which implies an increase of 21.66% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20.00 and $34.00 respectively. As a result, CBAY is trading at a discount of -77.73% off the target high and -4.55% off the low. For CymaBay Therapeutics stock forecast for 2023, 1 predictions are offered for each month of 2023 with average CymaBay Therapeutics stock forecast of $19.97, a high forecast of $19.97, and a low forecast of $19.97. The average CymaBay Therapeutics stock forecast 2023 represents a 4.58% increase from the last price of $19.1000003814697.September 8, 2023 at 1:12 PM · 3 min read. Shares of clinical-stage biopharmaceutical company CymaBay Therapeutics, Inc. CBAY gained after it announced positive top-line results from its late ...ACIU Stock 12 Months Forecast. Based on 2 Wall Street analysts offering 12 month price targets for AC Immune SA in the last 3 months. The average price target is $16.00 with a high forecast of $16.00 and a low forecast of $16.00. The average price target represents a 417.80% change from the last price of $3.09.According to . 9 Wall Street analysts that have issued a 1 year CBAY price target, the average CBAY price target is $24.56, with the highest CBAY stock price forecast at $34.00 and the lowest CBAY stock price forecast at $15.00. Stock Price Forecast The 8 analysts offering 12-month price forecasts for Cymabay Therapeutics Inc have a median target of 11.00, with a high estimate of. ... What is The target price for CBAY? The 8 analysts offering 12-month price forecasts for Cymabay Therapeutics Inc have a median target of 11.00, with a high estimate of 14.00 and a low …Risk and reward are the yin and yang of stock trading, the two opposite but essential ingredients in every market success. And there are no stocks that better embody both sides – the risk factors and the reward potentials – than penny stocks. These equities, priced below $5 per share, typically offer high upside potentials. Even a small gain in …

A high-level overview of CymaBay Therapeutics, Inc. (CBAY) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

A price increase of 41.9% over the past four weeks ensures that the trend is still in place for the stock of this company. Moreover, CBAY is currently trading at 92.9% of its 52-week High-Low ...

VKTX Signals & Forecast. The Viking Therapeutics stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some …The U.S. National Weather Service (NWS) is a part of the National Oceanic and Atmospheric Administration (NOAA). Many people rely on the National Weather Service’s forecasts in order to better anticipate what the weather will be like so the...The stock is selling for $9.87 and its $13.89 average price target suggests a 12-month upside potential of ~41%. (See CBAY stock forecast ) Cerevel Therapeutics ( CERE )Nov 29, 2023 · Predictions of CBAY stock price for tomorrow. 14-day Premium Trial Subscription Try For Free Get Free Stock Price Forecast. The 22 analysts offering 12-month price forecasts for Thermo Fisher Scientific Inc have a median target of 519.50, with a high estimate of 600.00 and a low estimate of 435.00 ...Wall Street Stock Market & Finance report, prediction for the future: You'll find the Coterra Energy share forecasts, stock quote and buy / sell signals below. According to present data Coterra Energy's CTRA shares and potentially its market environment have been in bearish cycle last 12 months (if exists).Stem, Inc. (NYSE:STEM) released its earnings results on Thursday, November, 2nd. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.01. The firm had revenue of $133.74 million for the quarter, compared to the consensus estimate of $182.46 million.Track Cymabay Therapeutics Inc (CBAY) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors CymaBay Therapeutics (CBAY) Stock Forecast & Price Target $17.90 -0.21 (-1.16%) (As of 11/22/2023 ET) Compare Share Today's Range $17.82 $18.45 50-Day …Cymabay Therapeutics Inc (NASDAQ:CBAY) trade information. Instantly CBAY has been showing red trend so far today with a performance of -1.24% on intraday trading today. The performance over the last five days has remained in the red territory. The company’s shares are currently up 186.68% year-to-date, but still down -3.67% over the last five ...3 Wall Street analysts have issued twelve-month target prices for Aldeyra Therapeutics' shares. Their ALDX share price targets range from $8.00 to $15.00. On average, they expect the company's share price to reach $12.33 in the next year. This suggests a possible upside of 370.7% from the stock's current price.What are analysts’ forecasts for CBAY stock? Forecst.com predicts future values using technical analysis of a large number of analytical parameters. CBAY stock returns are also predicted based on historical data. According to our research, CBAY stock is a bad long-term investment.

16 Wall Street analysts have issued 12 month price targets for Exelixis' stock. Their EXEL share price targets range from $18.00 to $32.00. On average, they anticipate the company's stock price to reach $25.44 in the next twelve months. This suggests a possible upside of 18.3% from the stock's current price. View analysts price …A price increase of 4.9% over the past four weeks ensures that the trend is still in place for the stock of this company. Moreover, CBAY is currently trading at 82.5% of its 52-week High-Low Range ...In a recent transaction on November 17, 2023, Charles Mcwherter, the President of Research and Development at CymaBay Therapeutics Inc (NASDAQ:CBAY), sold 11,342 shares of the company's stock ... Instagram:https://instagram. what is beta on stocksprrixshopify canadabest selling light beer há 6 dias ... ... CBAY's share price rises to $24.00, which is the median consensus price. At that level, CBAY's share price would be -31.87% below current price.According to CBAY; 1 in 1,000 women over the age of 40 live with PBC. Interested in CymaBay stock? Get a free CBAY Stock Research Report. Atara Bio (ATRA) Source: Shutterstock. why gold is so expensivetop video game stocks Apr 26, 2023 · (See CBAY stock forecast)Cerevel Therapeutics (CERE)The next Edelman choice is Cerevel, a company established in 2018 that specializes in the field of neuroscience. Cerevel's focus is on the ... You Should Look At The Stock Forecast For Cymabay Therapeutics Inc (NASDAQ: CBAY). Carlyle Group Inc (NASDAQ: CG): One Stock To Trade As Economic Progress Advances Why Invesco Ltd (NYSE: IVZ) Is A Stock Not To Be Discarded In 2023 Astrazeneca plc ADR (NASDAQ: AZN): A Stock Worth Thinking About Today Procter & … delaware mortgage lenders Sep 8, 2023 · CymaBay (CBAY) Stock Up on Positive Results From PBC Study. ... The median home sale price will fall 1.7% next year after eking out an anticipated 0.2% gain in 2023, according to the forecast. Find the latest Absci Corporation (ABSI) stock quote, history, news and other vital information to help you with your stock trading and investing.CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q3 2023 Earnings Call Transcript November 7, 2023 CymaBay Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.32 EPS, expectations were $-0.3. Operator: Good day, ladies and gentlemen, and welcome to CymaBay’s Third Quarter 2023 ...